EP Patent
EP3482754A1 — Pharmaceutical compositions and uses directed to lysosomal storage disorders
Assigned to Intrabio Ltd · Expires 2019-05-15 · 7y expired
What this patent protects
The present disclosure provides for treating lysosomal storage disorders (LSDs) comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof.
USPTO Abstract
The present disclosure provides for treating lysosomal storage disorders (LSDs) comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof.
Drugs covered by this patent
- Aqneursa (LEVACETYLLEUCINE) · Intrabio
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.